Abstract
Acute lung injury is a life-threating condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-α (TNF-α) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- α co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.
Keywords: Acute lung injury, secretory phospholipase A2, varespladib, surfactant.
Current Pharmaceutical Biotechnology
Title:Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture
Volume: 14 Issue: 4
Author(s): Daniele De Luca, Francesca Vendittelli, Joaquim Trias, Heather Fraser, Angelo Minucci, Leonarda Gentile, Jesus Perez-Gil, Giorgio Conti, Massimo Antonelli and Ettore D. Capoluongo
Affiliation:
Keywords: Acute lung injury, secretory phospholipase A2, varespladib, surfactant.
Abstract: Acute lung injury is a life-threating condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-α (TNF-α) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- α co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.
Export Options
About this article
Cite this article as:
Luca Daniele De, Vendittelli Francesca, Trias Joaquim, Fraser Heather, Minucci Angelo, Gentile Leonarda, Perez-Gil Jesus, Conti Giorgio, Antonelli Massimo and Capoluongo Ettore D., Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture, Current Pharmaceutical Biotechnology 2013; 14 (4) . https://dx.doi.org/10.2174/1389201011314040010
DOI https://dx.doi.org/10.2174/1389201011314040010 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Hepatobiliary Transporters by A Novel Kinase Inhibitor Contributes to Hepatotoxicity in Beagle Dogs
Drug Metabolism Letters Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Platinum Group Antitumor Chemistry: Design and development of New Anticancer Drugs Complementary to Cisplatin
Current Medicinal Chemistry Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets QSAR of SARS-CoV-2 Main Protease Inhibitors Utilizing Theoretical Molecular Descriptors
Letters in Drug Design & Discovery Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Binding Modes of 2-Phenylamino-6-oxopurines to Herpes Simplex Virus Thymidine Kinases
Letters in Drug Design & Discovery G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease
Current Topics in Medicinal Chemistry Comparative QSAR as a Cheminformatics Tool in the Design of Dihydro- Pyranone Based HIV-1 Protease Inhibitors
Current Computer-Aided Drug Design The Antioxidant Response Element and Oxidative Stress Modifiers in Airway Diseases
Current Molecular Medicine Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs
Current Pharmaceutical Design Computer Techniques for Drug Development from Thai Traditional Medicine
Current Pharmaceutical Design Recent Progress in the Development of Small Molecule c-Met Inhibitors
Current Topics in Medicinal Chemistry <i>Chemi-Informatic</i> Approach to Investigate Putative Pharmacoactive Agents of Plant Origin to Eradicate COVID-19
Coronaviruses Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Drugs for AIDS
Mini-Reviews in Medicinal Chemistry